Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNST
1926
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $4.42M | ﹤0.01% |
+93,779
| New | +$2.71M |
|
|
SUNE
1927
SUNation Energy
SUNE
$10.6M
| $4.4M | ﹤0.01% |
1
| – | – |
|
|
PRNB
1928
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $4.4M | ﹤0.01% |
+80,400
| New | +$3M |
|
|
FRBK
1929
DELISTED
Republic First Bancorp Inc
FRBK
| $4.4M | ﹤0.01% |
1,053,233
+382,300
| +57% | +$1.55M |
|
1930
Spyre Therapeutics
SYRE
$9.14B
| $4.4M | ﹤0.01% |
23,036
+608
| +3% | +$119K |
|
|
ARAV
1931
DELISTED
Aravive, Inc. Common Stock
ARAV
| $4.39M | ﹤0.01% |
321,304
+148,645
| +86% | +$1.31M |
|
|
ACH
1932
DELISTED
Alum Corp of China Ltd
ACH
| $4.39M | ﹤0.01% |
505,281
-1,919
| -0.4% | -$15.3K |
|
1933
Nexa Resources
NEXA
$1.88B
| $4.39M | ﹤0.01% |
539,300
-10,800
| -2% | -$98.5K |
|
1934
Natural Alternatives International
NAII
$12.8M
| $4.39M | ﹤0.01% |
549,598
+10,615
| +2% | +$89.7K |
|
1935
Vince Holding Corp
VNCE
$80.9M
| $4.39M | ﹤0.01% |
253,352
+89,001
| +54% | +$1.86M |
|
|
CTO
1936
CTO Realty Growth
CTO
$825M
| $4.38M | ﹤0.01% |
267,753
+50,397
| +23% | +$870K |
|
|
BHR
1937
Braemar Hotels & Resorts
BHR
$139M
| $4.37M | ﹤0.01% |
489,509
-41,120
| -8% | -$385K |
|
1938
Protagonist Therapeutics
PTGX
$10B
| $4.36M | ﹤0.01% |
618,124
+63,024
| +11% | +$626K |
|
|
CPLG
1939
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $4.35M | ﹤0.01% |
407,424
-9,176
| -2% | -$92.6K |
|
1940
Syndax Pharmaceuticals
SNDX
$1.77B
| $4.35M | ﹤0.01% |
495,500
-1,500
| -0.3% | -$11K |
|
|
PMD
1941
DELISTED
Psychemedics Corporation
PMD
| $4.35M | ﹤0.01% |
475,177
+22,311
| +5% | +$206K |
|
1942
Distribution Solutions Group
DSGR
$1.62B
| $4.34M | ﹤0.01% |
166,654
+32,654
| +24% | +$772K |
|
1943
Compugen
CGEN
$228M
| $4.33M | ﹤0.01% |
727,000
+88,400
| +14% | +$455K |
|
1944
Toll Brothers
TOL
$13.9B
| $4.32M | ﹤0.01% |
+109,300
| New | +$4.37M |
|
|
OMCC
1945
DELISTED
Old Market Capital Corp
OMCC
| $4.32M | ﹤0.01% |
523,755
-6,426
| -1% | -$57.1K |
|
1946
State Street SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
$3.36B
| $4.31M | ﹤0.01% |
146,100
-60,500
| -29% | -$1.79M |
|
|
TGB
1947
Trekor Metals
TGB
$3.06B
| $4.31M | ﹤0.01% |
8,979,157
+669,604
| +8% | +$283K |
|
1948
Red Rock Resorts
RRR
$3.76B
| $4.31M | ﹤0.01% |
179,800
+19,800
| +12% | +$440K |
|
|
TGA
1949
DELISTED
Transglobe Energy Corp
TGA
| $4.3M | ﹤0.01% |
3,116,913
+47,446
| +2% | +$59K |
|
1950
ICL Group
ICL
$7.16B
| $4.29M | ﹤0.01% |
895,675
+11,500
| +1% | +$53.1K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.